Currently, Mark W. Hahn is Chief Financial Officer of Verona Pharma Plc.

He is also on the board of ALSP Orchid Acquisition Corp. I.

In the past Mr. Hahn held the position of Chief Financial Officer at Charles & Colvard Ltd., Chief Financial Officer at Equitel, Inc., Chief Financial Officer & VP-Administration at Gigabeam Corp., Chief Financial Officer at BuildLinks, Inc., Chief Financial Officer for Athenix Corp., Chief Financial Officer & Executive Vice President at Cempra Pharmaceuticals, Inc., Chief Financial Officer & Executive Vice President at Cempra, Inc., Chief Financial Officer for Performaworks, Inc., Chief Financial Officer at Dova Pharmaceuticals, Inc. and Principal at Ernst & Young LLP.

Mr. Hahn received an undergraduate degree from the University of Wisconsin-Milwaukee.